Alnylam Pharmaceuticals, Inc. (ALNY)
Healthcare · end-of-day data as of Oct 16, 2026
The average 12-month analyst price target for ALNY is $374.49, 61.5% above the last close of $231.83 on Oct 16, 2026; targets range from $253.73 to $492.63. Rating consensus: Buy.
Snapshot
- P/E39.2x
- P/E vs sector+39.1%
- P/E vs own-92.9%
- Target upside+61.5%
- ConsensusBuy
- Market cap$31.02B
- FCF yield+1.7%
- Insiders-$399K
- Earnings in13d
- News
Why it moved
Alnylam Pharmaceuticals, Inc. (ALNY) fell 0.9% on Oct 16, 2026.
The market (SPY) fell 1.1%; Healthcare stocks fell 0.7%. Most of the move came from the market as a whole.
1 story on the day (30-day average 0.6).
Market = SPY. Sector = equal-weight average of the tracked companies in the same sector, net of the market.
Price and events
Last close $231.83 · -51.8% over 1y · E earnings · D dividend · S split · A analyst rating change
Technicals
- Trendsideways
- Sector▲ +16.0%
- MAs20▼ 50▼ 100▼ 200▼
- Above MAs0 of 4 above
- MA20×50Death 3d ago
- RSI47
- Support-4.2%
- Resistance+1.5%
- Off 52w high-52.8%
- Off ATH-52.8%
- 52w range$231.83
- Bollingerlower half
- MACD0.07
- ATR+4.0%
- Volume1.1x
Analyst price targets
18 firms with a target in the last 12 months · last close $231.83 · as of Oct 16, 2026
Strong buy 6 · Buy 17 · Hold 7 · Sell 0 · Strong sell 0
Revenue and free cash flow
Q2 FY2026: Revenue +66.9% year over year, free cash flow 3.1% of revenue, operating margin 17.9%.
| Q2 FY2026 | Jun 30, 2026 | $1.29B | 1.20 | $40.64M | 76.9% | 17.9% | 12.7% |
| Q1 FY2026 | Mar 31, 2026 | $1.17B | 1.51 | $48.67M | 81.9% | 23.0% | 17.6% |
| Q4 FY2025 | Dec 31, 2025 | $1.1B | 1.37 | $140M | 75.6% | 12.0% | 17.0% |
| Q3 FY2025 | Sep 30, 2025 | $1.25B | 1.84 | $313M | 84.2% | 29.5% | 20.1% |
| Q2 FY2025 | Jun 30, 2025 | $774M | -0.51 | $139M | 81.5% | -2.1% | -8.6% |
| Q1 FY2025 | Mar 31, 2025 | $594M | -0.44 | -$127M | 88.0% | 3.0% | -9.7% |
| Q4 FY2024 | Dec 31, 2024 | $593M | -0.65 | -$104M | 82.7% | -17.7% | -14.1% |
| Q3 FY2024 | Sep 30, 2024 | $501M | -0.87 | $39.52M | 82.9% | -15.4% | -22.3% |
Peers
| 20D | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1 |  | $499.74 | -1.8% | -10.4% | +14.0% | 29.1 | $127B | |
| 2 |  | $218.01 | -7.8% | -7.8% | -25.0% | — | $87.04B | |
| 3 |  | $790.74 | -0.7% | -7.2% | +8.7% | 19.6 | $81.41B | |
| 4 |  | $86.04 | -1.9% | -6.8% | +12.7% | 34.0 | $32.47B | |
| 5 |  | $69.57 | -1.1% | -21.0% | +20.2% | 20.2 | $31.42B | |
| 6 | | $231.83 | -0.9% | -52.8% | +61.5% | 39.2 | $31.02B | |
| 7 |  | $113.07 | -0.2% | -13.0% | +13.6% | 14.4 | $22.92B | |
| 8 |  | $72.57 | +0.1% | -0.1% | -7.0% | 62.6 | $11.38B |
Data as of Oct 16, 2026 close.
Latest news
Sentiment classified by AI from the headline (green positive, red negative). Links open the publisher.